75-50-3 manufacturers and suppliers on PharmaCompass

Chemistry

Click the arrow to open the dropdown
read-moreClick the button for full data set
Also known as: N,n-dimethylmethanamine, 75-50-3, Methanamine, n,n-dimethyl-, N-trimethylamine, Dimethylmethaneamine, Trimethylamine solution
Molecular Formula
C3H9N
Molecular Weight
59.11  g/mol
InChI Key
GETQZCLCWQTVFV-UHFFFAOYSA-N
FDA UNII
LHH7G8O305

75-50-3
Trimethylamine is a uremic toxin. Uremic toxins can be subdivided into three major groups based upon their chemical and physical characteristics: 1) small, water-soluble, non-protein-bound compounds, such as urea; 2) small, lipid-soluble and/or protein-bound compounds, such as the phenols and 3) larger so-called middle-molecules, such as beta2-microglobulin. Chronic exposure of uremic toxins can lead to a number of conditions including renal damage, chronic kidney disease and cardiovascular disease. Trimethylamine, also known as NMe3, N(CH3)3, and TMA, is a colorless, hygroscopic, and flammable simple amine with a typical fishy odor in low concentrations and an ammonia like odor in higher concentrations. Trimethylamine has a boiling point of 2.9 degree centigrade and is a gas at room temperature. Trimethylamine usually comes in pressurized gas cylinders or as a 40% solution in water. Trimethylamine is a nitrogenous base and its positively charged cation is called trimethylammonium cation. A common salt of trimethylamine is trimethylammonium chloride, a hygroscopic colorless solid. Trimethylamine is a product of decomposition of plants and animals. It is the substance mainly responsible for the fishy odor often associated with fouling fish, bacterial vagina infections, and bad breath. It is also associated with taking large doses of choline. Trimethylaminuria is a genetic disorder in which the body is unable to metabolize trimethylamine from food sources. Patients develop a characteristic fish odour of their sweat, urine, and breath after the consumption of choline-rich foods. Trimethylaminuria is an autosomal recessive disorder involving a trimethylamine oxidase deficiency. Trimethylaminuria has also been observed in a certain breed of Rhode Island Red chicken that produces eggs with a fishy smell.
1 2D Structure

75-50-3

2 Identification
2.1 Computed Descriptors
2.1.1 IUPAC Name
N,N-dimethylmethanamine
2.1.2 InChI
InChI=1S/C3H9N/c1-4(2)3/h1-3H3
2.1.3 InChI Key
GETQZCLCWQTVFV-UHFFFAOYSA-N
2.1.4 Canonical SMILES
CN(C)C
2.2 Other Identifiers
2.2.1 UNII
LHH7G8O305
2.3 Synonyms
2.3.1 MeSH Synonyms

1. Hbr Of Trimethylamine

2. Hcl Of Trimethylamine

3. Hi Of Trimethylamine

2.3.2 Depositor-Supplied Synonyms

1. N,n-dimethylmethanamine

2. 75-50-3

3. Methanamine, N,n-dimethyl-

4. N-trimethylamine

5. Dimethylmethaneamine

6. Trimethylamine Solution

7. (ch3)3n

8. Trimethyl Amine

9. Fema No. 3241

10. Trimethylamine Anhydrous

11. Trimethyl-amine

12. Un1083

13. Un1297

14. N,n,n-trimethylamine

15. Nme3

16. Ai3-15639

17. Trimethylamine, In Aqueous Solution

18. Trimethylamine Solution (30% Or Less)

19. Methylamine, N,n-dimethyl-

20. Lhh7g8o305

21. Chebi:18139

22. Mfcd00008327

23. Trimethylamine, Anhydrous [un1083] [flammable Gas]

24. Trimethylamin

25. Fema Number 3241

26. Trimethylamine, Aqueous Solutions Not >50% Trimethylamine, By Mass [un1297] [flammable Liquid]

27. Trimethylamine Solution, 25 Wt. % In H2o

28. Ccris 6283

29. Hsdb 808

30. Einecs 200-875-0

31. Unii-lhh7g8o305

32. Tri-methylamine

33. Ken

34. Dimethylamino Methane

35. Trimethylaminum

36. Tridimethylaminomethane

37. Trimethylamine, Anhydrous

38. N,n-dimethyl-methanamine

39. Dsstox_cid_6238

40. N,n-dimethylmethanamine #

41. Bmse000224

42. Ec 200-875-0

43. Trimethylamine [mi]

44. Dsstox_rid_78071

45. Nciopen2_007868

46. Trimethylamine [fcc]

47. Dsstox_gsid_26238

48. Dimethylaminomethylidyneradical

49. Trimethylamine [fhfi]

50. Trimethylamine [hsdb]

51. Trimethylamine, >=99.0%

52. Trimethylamine, >=99.5%

53. Trimethylamine 2.0m In Thf

54. Trimethylaminum [hpus]

55. Trimethylamine Aqueous Solution

56. Chembl439723

57. Gtpl5521

58. Dtxsid2026238

59. Trimethylamine 2m In Isopropanol

60. N(ch3)3

61. Trimethylamine Solution, 34-36%

62. Trimethylamine, Anhydrous, >=99%

63. Zinc8216125

64. Tox21_302355

65. Trimethylamine, 1m Solution In Thf

66. Bdbm50416499

67. Nsc101179

68. Stl264242

69. Akos000119986

70. Trimethylamine 2m Solution In Methanol

71. Trimethylamine Solution 20 % In H2o

72. Zinc112948558

73. Nsc-101179

74. Un 1083

75. Un 1297

76. Cas-75-50-3

77. Ncgc00255170-01

78. Trimethylamine, 45% W/w Aqueous Solution

79. Ft-0660006

80. T0464

81. T2268

82. T2704

83. T2892

84. T2893

85. T3567

86. T3614

87. T3847

88. C00565

89. Trimethylamine (ca.8% In N,n-dimethylformamide)

90. Trimethylamine Solution, 25 Wt. % In H2o, Fg

91. Trimethylamine Solution, 45 Wt. % In H2o, Fg

92. Q423953

93. Trimethylamine (ca. 8% In Toluene, Ca. 1mol/l)

94. Trimethylamine Solution, ~45 Wt. % In H2o (t)

95. Meldonium Dihydrate Impurity A [ep Impurity]

96. Acetylcholine Chloride Impurity C [ep Impurity]

97. Trimethylamine Solution, 25 Wt. % In Propylene Glycol

98. F1908-0091

99. Trimethylamine (~25 Wt. Per Cent Solution In Methanol)

100. Trimethylamine (ca. 13% In Acetonitrile, Ca. 2mol/l)

101. Trimethylamine (ca. 25% In Isopropyl Alcohol, Ca. 3mol/l)

102. Trimethylamine Solution (ca. 28% In Water, Ca. 4.3mol/l)

103. Trimethylamine Solution (ca. 25% In Isopropyl Alcohol, Ca. 3mol/l)

104. Trimethylamine, Anhydrous, Cylinder, With 316ss Needle Valve, 99%

105. Trimethylamine, Aqueous Solutions Not >50% Trimethylamine, By Mass

106. Hydrogen Undecahydrodicarbaundecaborate(1-), Compd. With Trimethylamine (1:1)

107. Trimethylamine Solution, 31-35 Wt. % In Ethanol, 4.2 M, Contains Toluene As Stabilizer

2.4 Create Date
2004-09-16
3 Chemical and Physical Properties
Molecular Weight 59.11 g/mol
Molecular Formula C3H9N
XLogP30.3
Hydrogen Bond Donor Count0
Hydrogen Bond Acceptor Count1
Rotatable Bond Count0
Exact Mass g/mol
Monoisotopic Mass g/mol
Topological Polar Surface Area3.2
Heavy Atom Count4
Formal Charge0
Complexity8
Isotope Atom Count0
Defined Atom Stereocenter Count0
Undefined Atom Stereocenter Count0
Defined Bond Stereocenter Count0
Undefined Bond Stereocenter Count0
Covalently Bonded Unit Count1
4 Pharmacology and Biochemistry
4.1 Absorption, Distribution and Excretion

The absorption, distribution, and biotransformation of TMA ... /was/ followed in rats given intravenous doses of 1 to 2 g/kg. TMA was rapidly distributed to tissues, especially the liver. In rats, TMA was 81% available after oral administration, reached a peak blood level 1 hour after oral administration, and was cleared with a half-life of 2 to 2.5 hours. When fed a synthetic diet, clearance showed a two-fold reduction. Conversion of TMA to its metabolite, trimethylamine-N-oxide, proceeded slowly in liver homogenates. In humans, TMA is formed in the intestinal tract from dietary choline. Large doses of choline result in disproportionately higher formation and urinary excretion of TMA. In newborn dairy calves, fecal trimethylamine levels are clearly higher in milk-fed calves and show huge elevations in diarrheic cases. Although fish is a major source of TMA in the diet, strawberries, kale juice, and garlic have been shown to increase urinary TMA levels.

American Conference of Governmental Industrial Hygienists. Documentation of the TLVs and BEIs with Other World Wide Occupational Exposure Values. 7th Ed. CD-ROM Cincinnati, OH 45240-1634 2013., p. 2


TMA penetrated both rat and human skin readily when applied to the epidermal surface with flux rates ranging from 3.4 to 265 ug/sq cm/hour in rats and from 0.98 to 92.7 ug/sq cm/hour in humans with dose applications of 0.1, 1, and 10 mg per 0.32 sq cm skin membrane. Both rat and human skin could act as a reservoir and evidence exists for small but detectable N-oxide forming during passage through the skin.

American Conference of Governmental Industrial Hygienists. Documentation of the TLVs and BEIs with Other World Wide Occupational Exposure Values. 7th Ed. CD-ROM Cincinnati, OH 45240-1634 2013., p. 2


... About 50% of the dose of trimethylamine hydrochloride (administered orally to dogs) was eliminated unchanged together with traces of dimethylamine, suggesting that trimethylamine was N-dealkylated.

Bingham, E.; Cohrssen, B.; Powell, C.H.; Patty's Toxicology Volumes 1-9 5th ed. John Wiley & Sons. New York, N.Y. (2001)., p. V4 713


It can be absorped through the skin and/or eye contact, inhalation, and ingestion (solution).

Sittig, M. Handbook of Toxic and Hazardous Chemicals and Carcinogens, 2002. 4th ed.Vol 1 A-H Norwich, NY: Noyes Publications, 2002., p. 2275


For more Absorption, Distribution and Excretion (Complete) data for Trimethylamine (6 total), please visit the HSDB record page.


4.2 Metabolism/Metabolites

When administered to humans, dogs, or rabbits, /trimethylamine/ is partly degraded to ammonia and subsequently to urea, and oxidized to trimethylamine oxide.

Bingham, E.; Cohrssen, B.; Powell, C.H.; Patty's Toxicology Volumes 1-9 5th ed. John Wiley & Sons. New York, N.Y. (2001)., p. V4 713


The Sperber technique of infusion into the renal portal circulation in chickens was used to investigate in vivo the renal tubular transport and renal metabolism of trimethylamine (TMA). When 14C-TMA was infused at a rate of 1 x 10(-9) mol/min the transport efficiency (TE), that is, the tubular excretion of the (14)C-label relative to excretion of simultaneously infused paminohippuric acid, was 0.70. Progressive addition of unlabeled TMA up to infusion rates of 1 x 10(-5) mol/min produced a progressive fall in the TE of the (14)C-label. Identification of the (14)C-label excreted in the urine revealed that approximately 85% of the infused (14)C-TMA was excreted by the infused kidney as a single metabolite over the entire range of infusions. By use of the techniques of low-voltage electrophoresis, high-voltage electrophoretic mobility-pH profile, and gas chromatography/mass spectrometry, the renal metabolite was found to be identical with standard (14)C-trimethylamine oxide (TMAO). At a TMA infusion rate of 1.5 x 10(-6) mol/kg/min reaching the infused kidney, the rate at which TMAO was formed and excreted by the kidney was 0.12 x 10(-6) mol per g of kidney per min. When (14)C-TMAO was infused into chickens its TE was 0.11, which was not evidence for active excretory transport. Infused TMA was almost entirely metabolized in vivo to its N-oxide, TMAO, which then entered the urine. The renal tubular excretion of (14)C during infusion of (14)C-TMA was inhibited by the cationic blocker of transport, quinine, and by the anionic blocker of transport, probenecid.

PMID:13980 Acara M et al; Drug Metab Dispos 5 (1): 82-90 (1977)


Humans ingest substantial amounts of choline and lecithin as part of common foods. Physicians have recently begun administering large doses of these compounds to individuals with neurological diseases. A significant fraction of ingested choline is destroyed by enzymes within gut bacteria, forming trimethylamine (TMA), dimethylamine (DMA) and monomethylamine (MMA). Some of these methylamines are eventually excreted into the urine, presumably after being absorbed and carried to the kidneys via the bloodstream. The methylamines formed after choline is eaten could be substrates for the formation of nitrosamines, which have marked carcinogenic activity. Twenty-seven millimoles of choline chloride, choline stearate or lecithin were administered to healthy human subjects. It was found that these treatments markedly increased the urinary excretion of TMA, DMA and MMA, with choline chloride having the greatest effect. Rats were treated with 2 mmol/kg b.wt. of choline chloride or lecithin, and it was found that these treatments significantly increased urinary TMA excretion and did not alter DMA or MMA excretion. Our choline chloride preparation contained no MMA, DMA or TMA; however, it was found that our choline stearate and all the commercially available lecithins tested were contaminated with methylamines. Prior removal of methylamines from our lecithin preparation minimized the effect of oral administration of this compound on methylamine excretion in urine of rats and humans.

PMID:6842395 Zeisel SH et al; J Pharmacol Exp Ther 225 (2): 320-4 (1983)


Flavin-containing monooxygenase form 3 (FMO3) is one of the major enzyme systems that protect humans from the potentially toxic properties of drugs and chemicals. Flavin-containing monooxygenase form 3 converts nucleophilic heteroatom-containing chemicals and endogenous materials to polar metabolites, which facilitates their elimination. For example, the tertiary amine trimethylamine is N-oxygenated by human flavin-containing monooxygenase form 3 to trimethylamine N-oxide, and trimethylamine N-oxide is excreted in a detoxication and deoderation process. In normal humans, virtually all trimethylamine is metabolized to trimethylamine N-oxide. In a few humans, trimethylamine is not efficiently metabolized to trimethylamine N-oxide, and those individuals suffer from trimethylaminuria, or fishlike odor syndrome. Previously ... mutations of the flavin-containing monooxygenase form 3 gene that cause trimethylaminuria /were identified/. /The authors/ report two prevalent polymorphisms of this gene (K158E and V257M) that modulate the activity of human monooxygenase form 3.

PMID:10640514 Cashman JR et al; Drug Metab Dispos 28 (2): 169-73 (2000)


For more Metabolism/Metabolites (Complete) data for Trimethylamine (10 total), please visit the HSDB record page.


Uremic toxins tend to accumulate in the blood either through dietary excess or through poor filtration by the kidneys. Most uremic toxins are metabolic waste products and are normally excreted in the urine or feces.


4.3 Biological Half-Life

In rats, TMA was 81% available after oral administration, reached a peak blood level 1 hour after oral administration, and was cleared with a half-life of 2 to 2.5 hours.

American Conference of Governmental Industrial Hygienists. Documentation of the TLVs and BEIs with Other World Wide Occupational Exposure Values. 7th Ed. CD-ROM Cincinnati, OH 45240-1634 2013., p. 2


Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty